These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 32348377)
1. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination. Parzych EM; Miura K; Long CA; Burns JM PLoS One; 2020; 15(4):e0232355. PubMed ID: 32348377 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys. Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW Malar J; 2016 Mar; 15():159. PubMed ID: 26975721 [TBL] [Abstract][Full Text] [Related]
4. Inclusion of an Optimized Eacret JS; Parzych EM; Gonzales DM; Burns JM J Immunol; 2021 Apr; 206(8):1817-1831. PubMed ID: 33789984 [No Abstract] [Full Text] [Related]
5. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487 [TBL] [Abstract][Full Text] [Related]
6. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate. Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576 [TBL] [Abstract][Full Text] [Related]
7. Production and preclinical evaluation of Plasmodium falciparum MSP-119 and MSP-311 chimeric protein, PfMSP-Fu24. Gupta PK; Mukherjee P; Dhawan S; Pandey AK; Mazumdar S; Gaur D; Jain SK; Chauhan VS Clin Vaccine Immunol; 2014 Jun; 21(6):886-97. PubMed ID: 24789797 [TBL] [Abstract][Full Text] [Related]
8. Conjugating recombinant proteins to Pseudomonas aeruginosa ExoProtein A: a strategy for enhancing immunogenicity of malaria vaccine candidates. Qian F; Wu Y; Muratova O; Zhou H; Dobrescu G; Duggan P; Lynn L; Song G; Zhang Y; Reiter K; MacDonald N; Narum DL; Long CA; Miller LH; Saul A; Mullen GE Vaccine; 2007 May; 25(20):3923-33. PubMed ID: 17428587 [TBL] [Abstract][Full Text] [Related]
9. A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies. Alaro JR; Partridge A; Miura K; Diouf A; Lopez AM; Angov E; Long CA; Burns JM Infect Immun; 2013 Oct; 81(10):3843-54. PubMed ID: 23897613 [TBL] [Abstract][Full Text] [Related]
10. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding. Kumar R; Angov E; Kumar N Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial. Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O; Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345 [TBL] [Abstract][Full Text] [Related]
12. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232 [TBL] [Abstract][Full Text] [Related]
13. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016 [TBL] [Abstract][Full Text] [Related]
14. Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes. Patra KP; Li F; Carter D; Gregory JA; Baga S; Reed SG; Mayfield SP; Vinetz JM Infect Immun; 2015 May; 83(5):1799-808. PubMed ID: 25690099 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax. Cao Y; Hayashi CTH; Araujo MDS; Tripathi AK; Andrade AO; Medeiros JF; Vinetz J; Kumar N Vaccine; 2024 Aug; 42(21):126140. PubMed ID: 39033079 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations. Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G Malar J; 2011 Dec; 10():359. PubMed ID: 22166048 [TBL] [Abstract][Full Text] [Related]
17. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536 [TBL] [Abstract][Full Text] [Related]
18. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the immunogenicity and vaccine potential of recombinant Plasmodium falciparum merozoite surface protein 8. Alaro JR; Angov E; Lopez AM; Zhou H; Long CA; Burns JM Infect Immun; 2012 Jul; 80(7):2473-84. PubMed ID: 22585960 [TBL] [Abstract][Full Text] [Related]
20. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]